Skip to main content
OpenTrials
Completed

NCT Number: NCT03248869

Asthma Mobile Health Application 2.0

Mobile health applications (MHA) are increasingly being explored as tools to assist in management of chronic diseases. Little is known regarding which characteristics of MHAs are effective and there is limited data suggesting a real-world impact on health outcomes. Asthma is one of the most common and costly of the chronic diseases, impacting a broad range of the population including both children and adults. It is a variable disease necessitating regular medication use, monitoring of symptoms, and avoidance of specific triggers. These characteristics of asthma make it a chronic disease that is particularly amenable to having an MHA facilitate active monitoring outside of periodic traditional medical visits. The study team has designed a MHA focused on asthma subjects to test the feasibility of an asthma mobile health application (AMHA). The AMHA 2.0 study is the result of a collaboration between MHA developers and Mount Sinai faculty with expertise in the fields of asthma, research design, data storage, and data analysis. AMHA 2.0 incorporated elements of usual clinical care (that may take place during typical office visits), such as medication reminders, a daily asthma diary to track asthma control (AC) and medication use, patient education and assessments of quality of life (QoL), and health care utilization (HCU).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dept. of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai

New York, 10029, United States

About this study

Mobile health applications (MHA) are increasingly being explored as tools to assist in management of chronic diseases. Little is known regarding which characteristics of MHAs are effective and there is limited data suggesting a real-world impact on health outcomes. Asthma is one of the most common and costly of the chronic diseases, impacting a broad range of the population including both children and adults. It is a variable disease necessitating regular medication use, monitoring of symptoms, and avoidance of specific triggers. These characteristics of asthma make it a chronic disease that is particularly amenable to having an MHA facilitate active monitoring outside of periodic traditional medical visits. The study team has designed a MHA focused on asthma subjects to test the feasibility of an asthma mobile health application (AMHA). The AMHA 2.0 study is the result of a collaboration between MHA developers and Mount Sinai faculty with expertise in the fields of asthma, research design, data storage, and data analysis. AMHA 2.0 incorporated elements of usual clinical care (that may take place during typical office visits), such as medication reminders, a daily asthma diary to track asthma control (AC) and medication use, patient education and assessments of quality of life (QoL), and health care utilization (HCU).

During the AMHA 2.0 study, the aims are to evaluate the feasibility of:

  • Consenting and enrolling a small cohort of subjects with asthma recruited from Mount Sinai pulmonary clinics remotely via downloading the app
  • Feasibility of use of an asthma e-diary and automated e-reminders for medications in this small cohort for one month
  • Exploring if a small cohort of participants will share data from wearable health and fitness monitoring devices if they own and use such devices.

The primary enrollment period for AMHA 2.0 was met in September 2015. More than 7,000 individuals e-consented for the AMHA 2.0 study, providing more than 80,000 survey responses with many participants granting AMHA 2.0 investigators access to geo-location and wellness data. Data collected during the first six months of the AMHA 2.0 study has provided evidence to answer all primary outcome measures.

Continuation of the AMHA 2.0 protocol was approved in December 2015, expanding the study to a larger population who will be followed for a more extended period of time and will be recruited via availability of the AMHA in the Apple App Store in the US, UK, and Ireland. The latest modification submitted in January, adds an entirely new aim, OM6 and SA6, to the project to include a genetics module. The objectives for the continuation study are:

  • To determine the feasibility of recruiting, consenting and enrolling a larger number of subjects remotely via the Apple App Store without direct participant contact during any phase of the study
  • Assess the impact of continued use of an asthma e-diary and automated medication e-reminders for up to 2 years
  • Explore the feasibility of sharing of data from wearable health and fitness monitoring devices (if applicable) from a larger cohort of patients for up to 2 years
  • To test the medical accuracy of algorithms that may be used in future app versions to give specific feedback to participants based on information they input into the AMHA
  • To investigate the association between DNA variants and asthma phenotypes including: asthma severity, symptom patterns, and medication use/response

This second phase of research is designed to continue the process of developing an AMHA that facilitates asthma self-monitoring, promotes positive behavioral changes, and reinforces adherence to treatment plans according to current asthma guidelines, all in a user-friendly fashion conducive to long term use.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Self-reported physician diagnosed asthma
  • Have an iPhone
  • Sufficient English-language ability to participate in informed consent process, complete study assessments and understand the text in mobile phone-delivered interventions

Exclusion criteria

  • <18 years of age
  • Not currently taking any asthma medications
  • Does not own an iPhone or know how to handle a mobile phone
  • Are unable to read or understand the study materials
  • Current pregnancy

Treatment and study plan

Current Daily Survey

Other

need description

Mobile health app

Other

Participants recruited, consented and enrolled via the AMHA and complete assessments using the app

Other names: Asthma Mobile Health App

Primary outcomes

  1. Number of downloads

    Time frame: 2 years

    Number of people who downloaded AMHA

  2. Percent of participants who aborted study participation

    Time frame: 2 years

    Percent of aborted study participants before completion inclusion/exclusion criteria

Secondary outcomes

  1. Frequency of use of the Daily asthma diary

    Time frame: 2 years

    Feasibility and implied participant acceptability by counting frequency of use of app

  2. Frequency of use of the Asthma Control (AC) questionnaire

    Time frame: 2 years

    Feasibility and implied participant acceptability by counting frequency of use of app

  3. Frequency of use of the Health Care Utilization (HCU) questionnaire

    Time frame: 2 years

    Feasibility and implied participant acceptability by counting frequency of use of app

  4. Percent of completion of Daily asthma diary

    Time frame: 2 years

    Feasibility and implied participant acceptability by counting percent of completion of features in AMHA

  5. Percent of completion of the Asthma Control (AC) questionnaire

    Time frame: 2 years

    Feasibility and implied participant acceptability by counting percent of completion of features in AMHA

  6. Percent of completion of the Health Care Utilization (HCU) questionnaire

    Time frame: 2 years

    Feasibility and implied participant acceptability by counting percent of completion of features in AMHA

  7. Frequency of use of optional AMHA features

    Time frame: 2 years

    Feasibility and implied participant acceptability by frequency of use of optional AMHA features

  8. Asthma Control (AC) questionnaire

    Time frame: up to 6 months

    Daily asthma diary to track asthma control. AC is based o modified GOAL criteria. Total scale range is from 0 (no impairment) 6 (maximal impairment for symptoms and rescue use)

  9. EuroQol 5D-5L (EQ-5D-5L)

    Time frame: up to 6 months

    EuroQol 5D-5L used to measure quality of life: 5 items are scored from 1 (no problems) to 5 (extreme severe problems). The numerals 1-5 have no arithmetic properties and should not be used as a cardinal scale. total of 3125 possible health states is defined in this way. Each state is referred to in terms of a 5 digit code. For example, state 11111 indicates no problems on any of the 5 dimensions, while state 55555 indicates severe problems in each item.

  10. Health Care Utilization (HCU) score

    Time frame: up to 6 months

    Questionnaire regarding HCU events with scores from 0 (no health services used to 10 (all health care service options utilized).

  11. Associations between genetic markers and asthma severity

    Time frame: 2 years

    Statistically significant associations between DNA variants and asthma severity. Clustering, regression, and ensemble statistical models will be employed to partition AMHA 2.0 participants into distinct phenotypic classes.

  12. Associations between genetic markers and symptom patterns

    Time frame: 2 years

    Statistically significant associations between DNA variants and symptom patterns. Clustering, regression, and ensemble statistical models will be employed to partition AMHA 2.0 participants into distinct phenotypic classes.

  13. Associations between genetic markers and medication use/response

    Time frame: 2 years

    Statistically significant associations between DNA variants and medication use/response. Clustering, regression, and ensemble statistical models will be employed to partition AMHA 2.0 participants into distinct phenotypic classes.

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Collaborators

  • Apple Inc.
  • Lifemap Solutions, Inc
  • Sage Bionetworks

Registry information

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Aug 14, 2017
Registry last updated
Aug 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.